Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Liver Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Solid Malignancies 1Seminoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Non Small Cell Lung Cancer NSCLC 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Metastatic Malignant Female Reproductive System Neoplasm 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Immunotherapy 1Hydronephrosis 1

Interventions

tremelimumab 1etoposide phosphate 1durvalumab 1Paclitaxel 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Germinoma × tremelimumab × Clear all
NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡